Catalyst Wire Dossier Catalyst Wire Dossier

Xiidra (lifitegrast ophthalmic solution) 5%

lifitegrast · Takeda Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Xiidra (lifitegrast ophthalmic solution) 5%, covering 2025-01-14 to 2025-01-14. Get the full timeline:

Most recent: Clinical Trial Update: Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers [Phase 4]

See pricing